Intellia Therapeutics (NTLA) Current Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Current Leases data on file, last reported at $19.1 million in Q1 2026.

• On a quarterly basis, Current Leases fell 50.74% year-over-year to $19.1 million in Q1 2026; TTM through Mar 2026 was $19.1 million, a 50.74% decrease from a year earlier, with the FY2025 full-year figure at $26.5 million, up 30.79% from the prior year.
• Current Leases for Q1 2026 stood at $19.1 million, down from $26.5 million in the prior quarter.
• Over the last five years, Current Leases for NTLA reached as high as $38.8 million in Q1 2025 and fell as low as $9.3 million in Q1 2022.
• Historically, Current Leases has averaged $19.6 million across 5 years, with a median of $18.8 million in 2024.
• Across the five-year window, Current Leases soared 106.59% in 2025 and slumped 50.74% in 2026, its largest moves.
• Year by year, Current Leases stood at $16.7 million in 2022, then climbed by 11.47% to $18.6 million in 2023, then increased by 8.86% to $20.2 million in 2024, then soared by 30.79% to $26.5 million in 2025, then declined by 27.89% to $19.1 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $19.1 million in Q1 2026, $26.5 million in Q4 2025, and $27.4 million in Q3 2025.